01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the midterm...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
21:39 , Apr 7, 2017 |  BioCentury  |  Politics, Policy & Law

Christmas in July

Every reauthorization of PDUFA has been accompanied by legislation giving FDA new missions or powers, and Congress is gearing up to continue the tradition of treating this must-pass legislation as a Christmas tree to be...
02:18 , Nov 12, 2016 |  BioCentury  |  Politics, Policy & Law

Character counts

Republican control of the Senate and House of Representatives is an unambiguous win for biopharma companies, but it is too early to judge what the election of Donald Trump as president will mean for an...
20:34 , Nov 9, 2016 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of N. meningitidis PilE could help identify epitopes for use in developing vaccines to prevent the infection. An atomic model of PilE generated from 1.44 angstrom (Å)-resolution crystal structures and c....
07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...